Adam Biczo, Arjun Sahgal, Jorrit-Jan Verlaan, Patel Shreyaskumar, Zsolt Szoverfi, Markus Schultheiss, Laurence Rhines, Jeremy Reynolds, Ilya Laufer, Alessandro Gasbarrini, Nicolas Dea, Ziya Gokaslan, Charles Fisher, Chetan Bettegowda, Stefano Boriani, Francis Hornicek, Rory Goodwin, Aron Lazary
{"title":"脊索瘤和软骨肉瘤靶向生物治疗的最新进展。","authors":"Adam Biczo, Arjun Sahgal, Jorrit-Jan Verlaan, Patel Shreyaskumar, Zsolt Szoverfi, Markus Schultheiss, Laurence Rhines, Jeremy Reynolds, Ilya Laufer, Alessandro Gasbarrini, Nicolas Dea, Ziya Gokaslan, Charles Fisher, Chetan Bettegowda, Stefano Boriani, Francis Hornicek, Rory Goodwin, Aron Lazary","doi":"10.1177/21925682241227917","DOIUrl":null,"url":null,"abstract":"<p><strong>Study design: </strong>Systematic review.</p><p><strong>Objectives: </strong>The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment.</p><p><strong>Methods: </strong>A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov.</p><p><strong>Results: </strong>A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified.</p><p><strong>Conclusions: </strong>There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.</p>","PeriodicalId":12680,"journal":{"name":"Global Spine Journal","volume":"15 1_suppl","pages":"120S-131S"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma.\",\"authors\":\"Adam Biczo, Arjun Sahgal, Jorrit-Jan Verlaan, Patel Shreyaskumar, Zsolt Szoverfi, Markus Schultheiss, Laurence Rhines, Jeremy Reynolds, Ilya Laufer, Alessandro Gasbarrini, Nicolas Dea, Ziya Gokaslan, Charles Fisher, Chetan Bettegowda, Stefano Boriani, Francis Hornicek, Rory Goodwin, Aron Lazary\",\"doi\":\"10.1177/21925682241227917\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Study design: </strong>Systematic review.</p><p><strong>Objectives: </strong>The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment.</p><p><strong>Methods: </strong>A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov.</p><p><strong>Results: </strong>A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified.</p><p><strong>Conclusions: </strong>There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.</p>\",\"PeriodicalId\":12680,\"journal\":{\"name\":\"Global Spine Journal\",\"volume\":\"15 1_suppl\",\"pages\":\"120S-131S\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Spine Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/21925682241227917\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Spine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/21925682241227917","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma.
Study design: Systematic review.
Objectives: The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment.
Methods: A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov.
Results: A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified.
Conclusions: There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.
期刊介绍：
Global Spine Journal (GSJ) is the official scientific publication of AOSpine. A peer-reviewed, open access journal, devoted to the study and treatment of spinal disorders, including diagnosis, operative and non-operative treatment options, surgical techniques, and emerging research and clinical developments.GSJ is indexed in PubMedCentral, SCOPUS, and Emerging Sources Citation Index (ESCI).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
